Greenland Mines Ltd Warrant
GRMLWStock
$0.17
Market Cap—
P/E—
Div yield—
Beta—
Price Chart
Favorite Metrics
Price vs S&P 500 (4W)-35.64%
VGM Score69.90
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GRMLWGreenland Mines Ltd Warrant | — | — | B | $0.17 |
| AMGNAmgen Inc | C | C | C | $352.82 |
| GILDGilead Sciences Inc | C | B | C | $123.84 |
| ARGXargenx SE American Depositary Shares | D | A | B | $888.65 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $178.17 |
| BIIBBiogen Inc. Common Stock | B | D | B | $201.96 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $90.00 |
| MRNAModerna, Inc. Common Stock | D | B | B | $59.75 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $164.18 |
| EXELExelixis Inc | C | B | B | $53.23 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $359.93 |
About
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.